Paula Anne Newman-Casey1, Leslie M Niziol2, Paul P Lee2, David C Musch3, Kenneth Resnicow4, Michele Heisler5. 1. Department of Ophthalmology and Visual Sciences, School of Medicine, University of Michigan, Ann Arbor, Michigan. Electronic address: panewman@med.umich.edu. 2. Department of Ophthalmology and Visual Sciences, School of Medicine, University of Michigan, Ann Arbor, Michigan. 3. Department of Ophthalmology and Visual Sciences, School of Medicine, University of Michigan, Ann Arbor, Michigan; Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan. 4. Department of Health Behavior and Health Education, School of Public Health, University of Michigan, Ann Arbor, Michigan. 5. Department of Health Behavior and Health Education, School of Public Health, University of Michigan, Ann Arbor, Michigan; Department of Internal Medicine, School of Medicine, University of Michigan, Ann Arbor, Michigan.
Abstract
PURPOSE: To assess the efficacy of the Support, Educate, Empower (SEE) glaucoma coaching program on medication adherence among glaucoma patients with low adherence. DESIGN: Uncontrolled intervention study with a pre-post design. PARTICIPANTS: Glaucoma patients ≥ age 40, taking ≥1 medication, who self-reported poor adherence were recruited from the University of Michigan Kellogg Eye Center. Adherence was monitored electronically for a 3-month baseline period; participants with median adherence of ≤80% were enrolled in the SEE program. METHODS: Participants' adherence was monitored electronically (AdhereTech, New York, NY) during the 7-month program. Adherence was calculated as the percentage of doses taken on time of those prescribed. The SEE program included (1) automated medication reminders, (2) 3 in-person counseling sessions with a glaucoma coach who had training in motivational interviewing (MI), and (3) 5 phone calls with the same coach for between-session support. The coach used a web-based tool to generate an education plan tailored to the patient's glaucoma diagnosis, test results, and ophthalmologist's recommendations (www.glaucomaeyeguide.org). The tool guided an MI-based conversation between coach and patient to identify barriers to adherence and possible solutions. Descriptive statistics were used to summarize baseline patient characteristics, and differences between those who did and did not complete the SEE program were tested with 2-sample t tests, chi-square tests, and Fisher exact tests. Adherence was compared before and after the SEE program with paired t tests. MAIN OUTCOME MEASURE: Change in electronically monitored medication adherence. RESULTS: A total of 48 participants were enrolled. The participants were 54% male, 46% white, and on average 64 years of age (standard deviation [SD], 10.8 years), with an average worse-eye mean deviation (MD) of -7.9 dB (SD, 8.8 dB). Those completing the SEE program (n = 39) did not differ significantly from those who dropped out (n = 9) on gender, race, age, MD, or baseline adherence. Medication adherence improved from 59.9% at baseline to 81.3% (P < 0.0001) after completing the SEE program. Ninety-five percent of participants showed an improvement in adherence (mean relative improvement, 21.4%; SD, 16.5%; range, -3.2% to 74.4%; median, 20.1%). Fifty-nine percent of participants showed adherence of >80% on completing the SEE program. CONCLUSIONS: The SEE program participants showed clinically meaningful, statistically significant improvement in glaucoma medication adherence.
PURPOSE: To assess the efficacy of the Support, Educate, Empower (SEE) glaucoma coaching program on medication adherence among glaucoma patients with low adherence. DESIGN: Uncontrolled intervention study with a pre-post design. PARTICIPANTS: Glaucoma patients ≥ age 40, taking ≥1 medication, who self-reported poor adherence were recruited from the University of Michigan Kellogg Eye Center. Adherence was monitored electronically for a 3-month baseline period; participants with median adherence of ≤80% were enrolled in the SEE program. METHODS: Participants' adherence was monitored electronically (AdhereTech, New York, NY) during the 7-month program. Adherence was calculated as the percentage of doses taken on time of those prescribed. The SEE program included (1) automated medication reminders, (2) 3 in-person counseling sessions with a glaucoma coach who had training in motivational interviewing (MI), and (3) 5 phone calls with the same coach for between-session support. The coach used a web-based tool to generate an education plan tailored to the patient's glaucoma diagnosis, test results, and ophthalmologist's recommendations (www.glaucomaeyeguide.org). The tool guided an MI-based conversation between coach and patient to identify barriers to adherence and possible solutions. Descriptive statistics were used to summarize baseline patient characteristics, and differences between those who did and did not complete the SEE program were tested with 2-sample t tests, chi-square tests, and Fisher exact tests. Adherence was compared before and after the SEE program with paired t tests. MAIN OUTCOME MEASURE: Change in electronically monitored medication adherence. RESULTS: A total of 48 participants were enrolled. The participants were 54% male, 46% white, and on average 64 years of age (standard deviation [SD], 10.8 years), with an average worse-eye mean deviation (MD) of -7.9 dB (SD, 8.8 dB). Those completing the SEE program (n = 39) did not differ significantly from those who dropped out (n = 9) on gender, race, age, MD, or baseline adherence. Medication adherence improved from 59.9% at baseline to 81.3% (P < 0.0001) after completing the SEE program. Ninety-five percent of participants showed an improvement in adherence (mean relative improvement, 21.4%; SD, 16.5%; range, -3.2% to 74.4%; median, 20.1%). Fifty-nine percent of participants showed adherence of >80% on completing the SEE program. CONCLUSIONS: The SEE program participants showed clinically meaningful, statistically significant improvement in glaucoma medication adherence.
Authors: Paula Anne Newman-Casey; Olivia Killeen; Sarah Miller; Chamisa MacKenzie; Leslie M Niziol; Ken Resnicow; John W Creswell; Paul Cook; Michele Heisler Journal: Health Commun Date: 2018-12-20
Authors: Niteesh K Choudhry; Alexis A Krumme; Patrick M Ercole; Charmaine Girdish; Angela Y Tong; Nazleen F Khan; Troyen A Brennan; Olga S Matlin; William H Shrank; Jessica M Franklin Journal: JAMA Intern Med Date: 2017-05-01 Impact factor: 21.873
Authors: Kevin G Volpp; Andrea B Troxel; Shivan J Mehta; Laurie Norton; Jingsan Zhu; Raymond Lim; Wenli Wang; Noora Marcus; Christian Terwiesch; Kristen Caldarella; Tova Levin; Mike Relish; Nathan Negin; Aaron Smith-McLallen; Richard Snyder; Claire M Spettell; Brian Drachman; Daniel Kolansky; David A Asch Journal: JAMA Intern Med Date: 2017-08-01 Impact factor: 21.873
Authors: Constance O Okeke; Harry A Quigley; Henry D Jampel; Gui-shuang Ying; Ryan J Plyler; Yuzhen Jiang; David S Friedman Journal: Ophthalmology Date: 2009-10-07 Impact factor: 12.079
Authors: David S Friedman; Steven R Hahn; Laurie Gelb; Jason Tan; Sonali N Shah; Elizabeth E Kim; Thom J Zimmerman; Harry A Quigley Journal: Ophthalmology Date: 2008-03-05 Impact factor: 12.079
Authors: Stephen J Walters; Inês Bonacho Dos Anjos Henriques-Cadby; Oscar Bortolami; Laura Flight; Daniel Hind; Richard M Jacques; Christopher Knox; Ben Nadin; Joanne Rothwell; Michael Surtees; Steven A Julious Journal: BMJ Open Date: 2017-03-20 Impact factor: 2.692
Authors: David J Miller; Leslie M Niziol; Angela R Elam; Michele Heisler; Paul P Lee; Kenneth Resnicow; David C Musch; Deborah Darnley-Fisch; Jamie Mitchell; Paula Anne Newman-Casey Journal: Ophthalmol Glaucoma Date: 2021-06-30
Authors: Juno Cho; Leslie M Niziol; Paul P Lee; Michele Heisler; Ken Resnicow; David C Musch; Paula Anne Newman-Casey Journal: Ophthalmol Glaucoma Date: 2021-08-04